GSK plc's filing reports that their drug Linerixibat has successfully met its primary endpoint in a Phase III trial for treating itching in patients with primary biliary cholangitis (PBC) as of November 19, 2024. The trial showed a significant improvement in itch scores over 24 weeks compared to placebo, indicating a promising treatment option for an estimated 240,000 patients with PBC.